Explainer · Longevity & Ageing
Semaglutide slowed measures of biological aging in a small trial
Researchers reanalyzed a 32-week trial of semaglutide in 84 adults and found the drug slowed several DNA-based clocks of biological aging. The aging analysis was exploratory, and the group studied was specific.
Based on a peer-reviewed study in Nature Communications
- In a 32-week randomized, placebo-controlled trial, 84 adults with HIV-associated lipohypertrophy took semaglutide or a placebo.
- Semaglutide slowed several second- and third-generation epigenetic clocks, including a 9% slower pace on the DunedinPACE clock (PhenoAge fell about 4.9 years per year).
- The epigenetic-aging analysis was post hoc: not what the trial was designed to test.
- Systems-based clocks showed parallel drops in inflammation, brain and heart aging measures.
- The authors call it a signal, not proof, and say purpose-built trials are needed before anyone uses the drug to slow aging.
The medicines behind Ozempic and Wegovy were designed to lower blood sugar and body weight. Now researchers are asking whether they do something more surprising: slow the body’s aging itself.
Scientists reexamined a 32-week randomized trial of semaglutide, the drug in Ozempic and Wegovy, and found that in 84 adults it reduced epigenetic aging across several DNA-based clocks compared with placebo. The work came from a team at UC San Diego School of Medicine and was published in Nature Communications. They call it a signal worth chasing, and no more than that.
What is an “aging clock”?
Your calendar age is fixed, but your body can run faster or slower than the years suggest. Epigenetic clocks try to read that pace. They detect DNA methylation, chemical marks on DNA that help regulate how genes are turned on or off without changing the genetic sequence itself. Because those marks drift with age in patterned ways, an algorithm can estimate a person’s biological age, and how fast it is moving, from a blood sample.
GLP-1 drugs, the class behind Ozempic, have been floated as possible anti-aging agents, but clinical-trial evidence for their effects on biological aging has been lacking. This analysis is among the first to look.
How solid is this?
The trial itself was strong: 32 weeks, randomized, double-blind, placebo-controlled, in 84 adults with a fat-redistribution condition linked to HIV. But the aging result did not come from what the trial set out to measure. Its primary endpoint was change in visceral adipose tissue, the deep abdominal fat; the epigenetic aging was not pre-specified. That makes it exploratory, a lead rather than a verdict.
What the clocks showed
Where the clocks moved, they moved meaningfully. The treated group aged about 9% slower on one pace-of-aging clock, and systems-based clocks showed parallel reductions in inflammation, brain, and heart aging measures. Several clocks tied to long-term health risk shifted in the same direction.
Why would a weight-loss drug touch aging at all? The researchers point to inflammation. By reducing inflammation and metabolic stress, they suggest, the drug lowers the chronic immune activation that helps drive accelerated aging, and it strips away the visceral fat that feeds those signals. Plausible, but unproven here.
The reasons for caution
The caveats are large, and, unusually, the authors lead with them: the post hoc design, the modest sample size, the HIV-specific cohort, and the 32-week follow-up. Epigenetic clocks are also proxies. They track patterns that go with aging, but slowing one is not the same as proven extra years of healthy life. The lead author, Michael Corley, put it plainly: “We are not saying that semaglutide reverses aging or makes people younger. What we are seeing is a signal that it may slow some of the biological processes associated with aging.”
What it means for you
For now, nothing changes. No one should take semaglutide to slow aging. It is a prescription drug with real side effects, approved for diabetes and obesity, and this study does not show it lengthens anyone’s life. What it does is make a serious case for the next experiment. The authors say prospective trials are needed to determine whether GLP-1 receptor agonists can be repurposed as gerotherapeutics, and larger trials will be needed to confirm the findings and pin down dosing.
For now it is a lead worth a proper trial, not a reason to reach for the drug.
People also ask
What is an epigenetic clock?
A test that estimates biological age from DNA methylation, chemical tags on DNA that switch genes on or off. As these tags shift with age in patterned ways, algorithms ('clocks' such as PhenoAge, GrimAge and DunedinPACE) read a person's biological age, or pace of aging, from a blood sample.
Does this mean semaglutide will help me live longer?
No. The study measured DNA-based markers of aging, not lifespan or disease, over eight months in a specific patient group. Slowing an epigenetic clock is a promising signal, but it has not been shown to translate into extra years or better health.
Should I take semaglutide to slow aging?
No. It is a prescription medicine with real side effects, approved for type 2 diabetes and obesity. This analysis does not support taking it to slow aging, and the researchers say larger, purpose-built trials are needed first.
Why were the participants people with HIV?
The original trial tested semaglutide for a fat-redistribution condition seen in some people with HIV. The researchers note that many of the biological processes involved in HIV also drive aging in the general population, but that still limits how far the finding can be generalized.